| Trial ID: | L2338 |
| Source ID: | NCT03893526
|
| Associated Drug: |
Entresto
|
| Title: |
Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
|
| Acronym: |
NEPT2D
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes
|
| Interventions: |
DRUG: Entresto|DRUG: Sitagliptin|DRUG: Valsartan|DRUG: Placebo
|
| Outcome Measures: |
Primary: Blood Glucose, Plasma Concentrations of glucose, 3 hours after treatment ( during the subsequent standardized meal) | Secondary: Plasma Concentrations of GLP-1, 3 hours after treatment ( during the subsequent standardized meal)|Plasma Concentrations of GIP, 3 hours after treatment ( during the subsequent standardized meal)|Plasma Concentrations of Glucagon, 3 hours after treatment ( during the subsequent standardized meal)|Plasma Concentrations of Insulin, 3 hours after treatment ( during the subsequent standardized meal)|Plasma Concentrations of C-Peptide, 3 hours after treatment ( during the subsequent standardized meal)|Plasma Concentrations of Amino Acids, 3 hours after treatment ( during the subsequent standardized meal)
|
| Sponsor/Collaborators: |
Sponsor: University of Copenhagen | Collaborators: Hvidovre University Hospital
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-01-25
|
| Completion Date: |
2021-03-01
|
| Results First Posted: |
|
| Last Update Posted: |
2021-05-05
|
| Locations: |
Hvidovre Hospital, Hvidovre, RegionH, 2650, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT03893526
|
